

71

Name of the Company PHARMAIDS PHARMACEUTICALS LIMITED

Statement of Profit and Loss for the period ended 31st December, 2017

Rs. In lakhs

	Particulars	Note No.	Qtr. Ended Unaudited 31.12.2017	Qtr. Ended Audited 30.09.2017	Qtr. Ended Unaudited 31.12.2016	Year to date figures for current period ended 31.12.2017	Year to date figures for previous period ended 31.12.2016	Year Ended Audited 31.03.2017
I	Revenue From Operations		17.32	4.90	29.08	41.80	94.46	120.25
II	Other Income		0.41	0.40	-	0.81	0.04	1.01
III	Total Income (I+II)		17.73	5.30	29.08	42.61	94.50	121.26
IV	EXPENSES							
	Cost of materials consumed		-	-	1.33	2.67	5.81	64.49
	Purchases of Stock-in-Trade		16.03	4.50	19.16	23.16	43.80	-
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress		0.06	(0.52)	(6.75)	20.73	0.47	2.95
	Employee benefits expense		1.14	1.62	3.26	6.28	14.72	16.63
	Finance costs		0.03	0.03	1.11	0.08	3.96	4.01
	Depreciation and amortization expense		0.02	0.02	1.96	0.04	5.88	6.37
	Other expenses		8.63	6.88	11.19	23.49	28.69	70.53
	Total expenses (IV)		25.91	12.53	31.26	76.45	103.33	164.98
V	Profit/(loss) before exceptional items and tax (III- IV)		(8.18)	(7.23)	(2.18)	(33.84)	(8.83)	(43.72)
VI	Exceptional Items				-	-	-	51.97
VII	Profit/(loss) before tax (V+VI)		(8.18)	(7.23)	(2.18)	(33.84)	(8.83)	8.25
VIII	Tax expense:							
	(1) Current tax Adj. of earlier year		-	1.75	-	1.75	-	-
	(2) Deferred tax		-	-	-	-	-	(2.72)
IX	Profit (Loss) for the period from continuing operations (VII-VIII)		(8.18)	(8.98)	(2.18)	(35.59)	(8.83)	10.97
X	Profit/(loss) from discontinued operations		-	-	-	-	-	-
XI	Tax expense of discontinued operations		-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)		(8.18)	(8.98)	(2.18)	(35.59)	(8.83)	10.97
XIV	Other Comprehensive Income		-	-	-	-	-	-
	A (i) Items that will not be reclassified to profit or loss		-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss		-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)		-	-	-	-	-	-
XVI	Earnings per equity share (for continuing operation):		-	-	-	-	-	-
	(1) Basic		(0.24)	(0.26)	(0.06)	(1.05)	(0.26)	0.32
	(2) Diluted		(0.24)	(0.26)	(0.06)	(1.05)	(0.26)	0.32
XVII	Earnings per equity share (for discontinued operation):							
	(1) Basic							
	(2) Diluted							
XVII	Earnings per equity share (for							


**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 15th February, 2018. 2. The Un-Audited Financial Results for the Quarter ended 31st December, 2017 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013. 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. 4) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only 5) Provision for Income Tax and Deffered Tax will be made at the end of the Financial year.

**Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 30 June 2017 and year ended 31 March 2017 is as follows:**

Particulars	Quarter Ended			Six months Ended	Year to date figures	Year ended
	Qtr. Ended Unaudited 31.12.2017	Qtr. Ended Audited 30.09.2017	Qtr. Ended Unaudited 31.12.2016	Year to date figures for current period ended 31.12.2017	for previous period ended 31.12.2016	Year Ended Audited 31.03.2017
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net profit reported for the quarter earlier as per the previous Indian GAAP	(8.18)	(8.98)	(2.18)	(35.59)	(8.83)	10.97
Net profit for the period as per Ind AS	(8.18)	(8.98)	(2.18)	(35.59)	(8.83)	10.97
Other Comprehensive Income	-	-	-	-	-	-
Total Comprehensive Income for the period as per Ind AS	(8.18)	(8.98)	(2.18)	(35.59)	(8.83)	10.97

For PHARMAIDS PHARMACEUTICALS LIMITED

DR. GHISULAL JAIN  
MANAGING DIRECTOR

Place : Hyderabad

Date : 15-02-2018